AgingResearch.NewsJoin free

Phase 1Completed

Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma

Phase 1 Trial of Tolerance and Pharmacokinetic of Chlorogenic Acid for Injection in the Advanced Glioblastoma Patients

Sponsor
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd (Industry)
Enrollment
26 enrolled
Conditions
Glioblastoma
Interventions
Chlorogenic acid
Ages
adults, older adults
Registry
NCT02728349

Full record on ClinicalTrials.gov

From the registry

The purpose of this study: Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the advanced Glioblastoma Patients ;

Primary outcomes

  • Number of adverse events
  • Number of participants with treatment-related adverse events as assessed by CTCAE v4.0，grade ≥3 (DLT)
  • Maximum Tolerated Dose
  • Area under the plasma concentration versus time curve (AUC) of chlorogenic acid

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Started

  5. Registered